Loading...
Loading...
In a report published Monday, Credit Suisse analyst Bruce Nudell initiated coverage on
Trivascular TechnologiesTRIV with an Outperform rating and $17.00 price target.
In the report, Credit Suisse noted, “TRIV is a relatively new entrant in the $1.2B WW endovascular aortic repair (EVAR) market. EVAR is an alternative to open surgery in the treatment of abdominal aortic aneurysms (AAA), a fatal disease if left untreated. While the EVAR market is competitive and well penetrated (we forecast 5% market growth going forward) we believe TRIV's Ovation device is differentiated enough (as described below) to take share from larger competitors. We project TRIV reaching ~10%/13% share of the WW AA market by in sales terms by 2020/2030.”
Trivascular Technologies closed on Friday at $12.92.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in